2
Registered trials
1
Recruiting
2
Unique sponsors
2
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Phase II/III:
1
Phase I (First in Human):
1
Phase II/III
1 trial-
EndedImmutep CommercialEFTILAGIMOD ALFA
Phase I (First in Human)
1 trial-
RecruitingDaiichi Sankyo Inc. CommercialDS-3939A
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Immutep | Commercial | 1 | Phase II/III | 0 |
| Daiichi Sankyo Inc. | Commercial | 1 | Phase I (First in Human) | 1 |
New trials by year
2023
1
2025
1